Evidence map›Paper›PMID 31807751›Full record

ArticleInflammatory bowel diseases2020

Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn's-Like Ileitis by Suppressing Thymocyte Maturation.

Thangaraj Karuppuchamy, Christopher J Tyler, Luke R Lundborg, Tamara Pérez-Jeldres, Abigail K Kimball, Eric T Clambey, Paul Jedlicka, Jesús Rivera-Nieves

Open access · bronzeAbstract read
In one paragraph

Article in Inflammatory bowel diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Frontiers in pharmacology · 2022
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. A Bioassay Using a Pentadecanal Derivative to Measure S1P Lyase Activity.International journal of molecular sciences · 2021
    Article
  16. Review
  17. The Swing of Lipids at Peroxisomes and Endolysosomes in T Cell Activation.International journal of molecular sciences · 2020
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Thangaraj KaruppuchamyInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Christopher J TylerInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Luke R LundborgInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Tamara Pérez-JeldresUniversidad Católica de Chile, Santiago, Chile.
Abigail K KimballDepartment of Anesthesiology Aurora, Colorado, USA.
Eric T ClambeyDepartment of Anesthesiology Aurora, Colorado, USA.
Paul JedlickaDepartment of Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.
Jesús Rivera-NievesInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
University of California, San Diego · USThe Medical Center of Aurora · USHospital San Borja Arriarán · CLUniversity of Colorado Anschutz Medical Campus · US

Funding

The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Theresa Torres Pizarro · 2015 to 2026
$15.6M
Novel Traffic-targeted Therapies for IBDR01DK108670 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RIVERA-NIEVES, JESUS · 2016 to 2020
$3.3M
Immunoprofiling for identifying biomarkers in celiac diseaseR21AI149636 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ERNST, PETER B., RIVERA-NIEVES, JESUS · 2020 to 2021
$433k
BLRD VA I01 BX003436NIAID NIH HHS R21 AI149636NIDDK NIH HHS P30 DK097948NIDDK NIH HHS R01 DK108670
6 · The paper itself

Abstract

backgroundLymphocytes recirculate from tissues to blood following the sphingosine-1-phosphate (S1P) gradient (low in tissues, high in blood), maintained by synthetic and degradative enzymes, among which the S1P lyase (SPL) irreversibly degrades S1P. The role of SPL in the intestine, both during homeostasis and IBD, is poorly understood. We hypothesized that modulation of tissue S1P levels might be advantageous over S1P receptor (S1PR) agonists (eg, fingolimod, ozanimod, etrasimod), as without S1PR engagement there might be less likelihood of potential off-target effects.

methodsFirst we examined SPL mRNA transcripts and SPL localization in tissues by quantitative reverse transcription polymerase chain reaction and immunohistochemistry. The in vivo effects of the SPL inhibitors 4-deoxypyridoxine hydrochloride (30 mg/L) and 2-acetyl-4 (tetrahydroxybutyl)imidazole (50 mg/L) were assessed through their oral administration to adult TNF∆ARE mice, which spontaneously develop Crohn's-like chronic ileitis. The effect of SPL inhibition on circulating and tissue lymphocytes, transcriptional regulation of proinflammatory cytokines, and on the histological severity of ileitis was additionally examined. Tissue S1P levels were determined by liquid chromatography-mass spectrometry. Mechanistically, the potential effects of high S1P tissue levels on intestinal leukocyte apoptosis were assessed via terminal deoxynucleotidyl transferase dUTP nick end-labeling assay and annexin 5 staining. Finally, we examined the ability of T cells to home to the intestine, along with the effects of SPL inhibition on cellular subsets within immune compartments via flow and mass cytometry.

resultsS1P lyase was ubiquitously expressed. In the gut, immunohistochemistry predominantly localized it to small intestinal epithelia, although the lamina propria leukocyte fraction had higher mRNA transcripts. Inhibition of SPL markedly increased local intestinal S1P levels, induced peripheral lymphopenia, downregulated proinflammatory cytokines, and attenuated chronic ileitis in mice. SPL inhibition reduced T and myeloid cells in secondary lymphoid tissues and the intestine and decreased naïve T-cell recruitment. The anti-inflammatory activity of SPL inhibition was not mediated by leukocyte apoptosis, nor by interference with the homing of lymphocytes to the intestine, and was independent of its peripheral lymphopenic effect. However, SPL inhibition promoted thymic atrophy and depleted late immature T cells (CD4+CD8+ double positive), with accumulation of mature CD4+CD8- and CD4-CD8+ single-positive cells.

conclusionsInhibition of the S1P lyase alters the S1P gradient and attenuates chronic ileitis via central immunosuppression. SPL inhibition could represent a potential way to tame an overactive immune response during IBD and other T-cell-mediated chronic inflammatory diseases.

Indexed as

Aldehyde-LyasesAnimalsAnti-Inflammatory AgentsCrohn DiseaseIleitisLysophospholipidsMiceSphingosineThymocytesTumor Necrosis Factor-alphaAldehyde-LyasesAnti-Inflammatory AgentsLysophospholipidsSphingosinesphingosine 1-phosphatesphingosine 1-phosphate lyase (aldolase)Tumor Necrosis Factor-alphainflammatory bowel diseaseS1P gradientT cellsthymic atrophy

Identifiers

PMID31807751
PMCPMC6943703
OpenAlexW2992928368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.